FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Francesco Passamonti

Research Profile

Chemicals & Drugs

Disorders

Physiology

Mutation

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Co-author Network

Publications

TOP 3
Michele Merli; Lorena Appio; Luca Arcaini; Claudia Basilico; Domenica Caramazza; Andrea Ferrario; Margherita Maffioli; Francesco Passamonti
Novel agents in indolent lymphomas.
Alessandro Squizzato; Francesco Passamonti; Erica Romualdi; Saskia Middeldorp
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Tiziano Barbui; Irene Bertozzi; Silvia Betti; Veronika Buxhofer-Ausch; Alessandra Carobbio; Valerio De Stefano; Guido Finazzi; Heinz Gisslinger; Francesco Passamonti; Alessandro Rambaldi; Maria Luigia Randi; Francesco Rodeghiero; Marco Ruggeri; Elisa Rumi; Juergen Thiele; Alessandro M Vannucchi; Ayalew Tefferi
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Francesco Passamonti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michele Merli; Lorena Appio; Luca Arcaini; Claudia Basilico; Domenica Caramazza; Andrea Ferrario; Margherita Maffioli; Francesco Passamonti
Novel agents in indolent lymphomas.
Therapeutic advances in hematology 2013;4(2):133-48.
2013: Alessandro Squizzato; Francesco Passamonti; Erica Romualdi; Saskia Middeldorp
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Cochrane database of systematic reviews (Online) 2013;4():CD006503.
2012: Tiziano Barbui; Irene Bertozzi; Silvia Betti; Veronika Buxhofer-Ausch; Alessandra Carobbio; Valerio De Stefano; Guido Finazzi; Heinz Gisslinger; Francesco Passamonti; Alessandro Rambaldi; Maria Luigia Randi; Francesco Rodeghiero; Marco Ruggeri; Elisa Rumi; Juergen Thiele; Alessandro M Vannucchi; Ayalew Tefferi
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
Blood 2012;120(26):5128-33; quiz 5252.
2012: Francesco Passamonti; Andrea Ferrario; Margherita Maffioli; Michele Merli; Domenica Caramazza
Clinical predictors of outcome in MPN.
Hematology/oncology clinics of North America 2012;26(5):1101-16.
2012: Francesco Passamonti; Maria Luigia Randi; Francesco Rodeghiero; Marco Ruggeri; Elisa Rumi; Jürgen Thiele; Alessandro Maria Vannucchi; Elisabetta Antonioli; Tiziano Barbui; Irene Bertozzi; Emanuela Boveri; Veronika Buxhofer-Ausch; Domenica Caramazza; Alessandra Carobbio; Valentina Carrai; Mario Cazzola; Emanuele S G d'Amore; Naseema Gangat; Andrea Gianatti; Francois Girodon; Bettina Gisslinger; Heinz Gisslinger; Curtis A Hanson; Hans Michael Kvasnicka; Margherita Maffioli; Filippo Marino; Leonhard Müllauer; Cristiana Pascutto; Ayalew Tefferi
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Blood 2012;120(6):1197-201.
2012: Srdan Verstovsek; Sherry Pierce; Ester Pungolino; Elisa Rumi; Deborah A Thomas; Gautam Borthakur; Domenica Caramazza; Mario Cazzola; Jorge E Cortes; Zeev Estrov; Elias Jabbour; Tapan Kadia; Hagop M Kantarjian; Enrica Morra; Francesco Passamonti
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Blood 2012;120(6):1202-9.
2012: Alessandra Carobbio; Guido Finazzi; Naseema Gangat; Heinz Gisslinger; Hans Michael Kvasnicka; Maria Luigia Randi; Francesco Passamonti; Alessandro Rambaldi; Francesco Rodeghiero; Marco Ruggeri; Elisa Rumi; Ayalew Tefferi; Juergen Thiele; Alessandro M Vannucchi; Elisabetta Antonioli; Irene Bertozzi; Veronika Buxhofer-Ausch; Tiziano Barbui
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.
American journal of hematology 2012;87(2):203-4.
2012: Elisa Rumi; Ilaria Ambaglio; Ilaria Casetti; Mario Cazzola; Chiara Elena; Cristiana Pascutto; Francesco Passamonti; Daniela Pietra
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm.
American journal of hematology 2012;87(1):129-30.
2011: Elisa Rumi; Klaudia Bagienski; Tiina Berg; Ilaria Casetti; Chiara Elena; Ashot Harutyunyan; Thorsten Klampfl; Robert Kralovics; Cristiana Pascutto; Francesco Passamonti; Daniela Pietra; Mario Cazzola
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.
American journal of hematology 2011;86(12):974-9.
2011: Chiara Elena; Cristiana Pascutto; Monica Portolan; Elisa Rumi; Matteo Della Porta; Francesco Passamonti
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.
Haematologica 2011;96(8):1236-8.
2011: Thorsten Klampfl; Klaudia Bagienski; Tiina Berg; Mario Cazzola; Bettina Gisslinger; Heinz Gisslinger; Paola Guglielmelli; Ashot Harutyunyan; Ilaria Iacobucci; Roland Jäger; Giovanni Martinelli; Damla Olcaydu; Francesco Passamonti; Lisa Pieri; Daniela Pietra; Elisa Rumi; Martin Schalling; Alessandro M Vannucchi; Robert Kralovics
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.
Blood 2011;118(1):167-76.
2011: Francesco Passamonti
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Clinical lymphoma, myeloma & leukemia 2011;11 Suppl 1():S25-7.
2011: Daniela Pietra; Angela Brisci; Elisa Rumi; Sabrina Boggi; Chiara Elena; Alessandro Pietrelli; Roberta Bordoni; Maurizio Ferrari; Francesco Passamonti; Gianluca De Bellis; Laura Cremonesi; Mario Cazzola
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.
Haematologica 2011;96(4):607-11.
2011: Damla Olcaydu; Elisa Rumi; Ashot Harutyunyan; Francesco Passamonti; Daniela Pietra; Cristiana Pascutto; Tiina Berg; Roland Jäger; Emma Hammond; Mario Cazzola; Robert Kralovics
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Haematologica 2011;96(3):367-74.
2011: Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.
Haematologica 2011;96(3):454-8.
2011: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegård; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben A Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(6):761-70.
2010: Michele Merli; Luca Arcaini; Emanuela Boveri; Sara Rattotti; Cristina Picone; Francesco Passamonti; Annamaria Tenore; Laura Sozzani; Marco Lucioni; Marzia Varettoni; Silvia Rizzi; Lucia Morello; Virginia Ferretti; Cristiana Pascutto; Marco Paulli; Mario Lazzarino
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.
European journal of haematology 2010;85(5):405-15.
2010: Silvia Zibellini; Daniela Capello; Francesco Forconi; Paolo Marcatili; Davide Rossi; Sara Rattotti; Silvia Franceschetti; Elisa Sozzi; Emanuele Cencini; Marasca Roberto; Luca Baldini; Alessandra Tucci; Francesco Bertoni; Francesco Passamonti; Ester Orlandi; Marzia Varettoni; Michele Merli; Silvia Rizzi; Valter Gattei; Anna Tramontano; Marco Paulli; Gianluca Gaidano; Luca Arcaini
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.
Haematologica 2010;95(10):1792-6.
2010: R Jäger; Heinz Gisslinger; Francesco Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; Robert Kralovics
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.
Leukemia 2010;24(7):1290-8.
2010: Marco Paulli; Luca Arcaini; Marco Lucioni; Emanuela Boveri; Daniela Capello; Francesco Passamonti; Michele Merli; S Rattotti; Davide Rossi; Roberta Riboni; E Berti; Umberto Magrini; R Bruno; Gianluca Gaidano; Mario Lazzarino
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(6):1189-95.
2010: Luca Arcaini; Michele Merli; Francesco Passamonti; Silvia Rizzi; Virginia Ferretti; Sara Rattotti; Cristiana Pascutto; Marco Paulli; Mario Lazzarino
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients.
British journal of haematology 2010;149(3):455-7.
2010: Elisa Rumi; Francesco Passamonti; Paolo Bernasconi; Luca Arcaini; Daniela Pietra; Chiara Elena; Emanuela Boveri; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Validation of cytogenetic-based risk stratification in primary myelofibrosis.
Blood 2010;115(13):2719-20.
2010: Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Blood 2010;115(9):1703-8.
2010: Luca Arcaini; Michele Merli; Francesco Passamonti; Raffaele Bruno; Ercole Brusamolino; Paolo Sacchi; Sara Rattotti; Ester Orlandi; Elisa Rumi; Virginia Ferretti; Silvia Rizzi; Erika Meli; Cristiana Pascutto; Marco Paulli; Mario Lazzarino
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.
American journal of hematology 2010;85(1):46-50.
2009: Francesca Novara; Luca Arcaini; Michele Merli; Francesco Passamonti; Silvia Zibellini; Silvia Rizzi; Sara Rattotti; Elisa Rumi; Cristiana Pascutto; Annalisa Vetro; Cesare Astori; Emanuela Boveri; Marco Lucioni; Marco Paulli; Orsetta Zuffardi; Mario Lazzarino
High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma.
Human pathology 2009;40(11):1628-37.
2009: Luca Malcovati; Matteo G Della Porta; Daniela Pietra; Emanuela Boveri; Andrea Pellagatti; Anna Gallì; Erica Travaglino; Angela Brisci; Elisa Rumi; Francesco Passamonti; Rosangela Invernizzi; Laura Cremonesi; Jacqueline Boultwood; james wainscoat; Eva Hellström-Lindberg; Mario Cazzola
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Blood 2009;114(17):3538-45.
2009: Francesco Passamonti; Elisa Rumi; Luca Arcaini; Chiara Elena; Carlo Castagnola; Patrizia Zappasodi; Paolo Bernasconi; Daniela Pietra; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Blast phase of essential thrombocythemia: A single center study.
American journal of hematology 2009;84(10):641-4.
2009: Luca Arcaini; Silvia Zibellini; Francesco Passamonti; Sara Rattotti; Marco Lucioni; Rosangela Invernizzi; Michele Merli; Silvia Rizzi; Emanuela Boveri; Elisa Rumi; Cesare Astori; Cristina Picone; Marzia Varettoni; Cristiana Pascutto; Marco Paulli; Mario Lazzarino
Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.
Blood cells, molecules & diseases 2009;42(3):286-91.
2009: Luca Arcaini; Cristiana Pascutto; Francesco Passamonti; RAFFAELE BRUNO; Michele Merli; Silvia Rizzi; Ester Orlandi; Cesare Astori; Sara Rattotti; Marco Paulli; Mario Lazzarino
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.
International journal of cancer. Journal international du cancer 2009;124(9):2246-9.
2009: Matteo Della Porta; Luca Malcovati; Emanuela Boveri; Erica Travaglino; Daniela Pietra; Cristiana Pascutto; Francesco Passamonti; Rosangela Invernizzi; Alessandro Castello; Umberto Magrini; Mario Lazzarino; Mario Cazzola
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):754-62.
2009: Elisa Rumi; Francesco Passamonti; L Pagano; M Ammirabile; Luca Arcaini; Chiara Elena; A Flagiello; R Tedesco; Cristina Vercellati; A P Marcello; Daniela Pietra; Remigio Moratti; Mario Cazzola; Mario Lazzarino
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.
Journal of internal medicine 2009;265(2):266-74.
2009: Francesco Passamonti
New and old prognostic factors in polycythemia vera.
Current hematologic malignancy reports 2009;4(1):19-24.
2009: Francesco Passamonti; Elisa Rumi
Clinical relevance of JAK2 (V617F) mutant allele burden.
Haematologica 2009;94(1):7-10.
2008: Francesco Passamonti; Elisa Rumi; Luca Arcaini; Emanuela Boveri; Chiara Elena; Daniela Pietra; Sabrina Boggi; Cesare Astori; Paolo Bernasconi; Marzia Varettoni; Ercole Brusamolino; Cristiana Pascutto; Mario Lazzarino
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
Haematologica 2008;93(11):1645-51.
2008: Elisa Rumi; Francesco Passamonti; Cristina Picone; Matteo Giovanni Della Porta; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Disease anticipation in familial myeloproliferative neoplasms.
Blood 2008;112(6):2587-8; author reply 2588-9.
2008: Luca Arcaini; Francesca Montanari; Emilio Paolo Alessandrino; Alessandra Tucci; Ercole Brusamolino; Livio Gargantini; Roberto Cairoli; Paolo Bernasconi; Francesco Passamonti; Maurizio Bonfichi; V Zoli; C Bottelli; Silvia Calatroni; Daniela Troletti; Michele Merli; Cristiana Pascutto; I Majolino; Giuseppe Rossi; Enrica Morra; Mario Lazzarino
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(7):1331-5.
2008: Francisco Cervantes; Francesco Passamonti; Giovanni Barosi
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.
Leukemia 2008;22(5):905-14.
2008: Francesco Passamonti; Elisa Rumi; Marianna Caramella; Chiara Elena; Luca Arcaini; Emanuela Boveri; Cecilia Del Curto; Daniela Pietra; Laura Vanelli; Paolo Bernasconi; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Blood 2008;111(7):3383-7.
2008: Daniela Pietra; Sai Li; Angela Brisci; Francesco Passamonti; Elisa Rumi; Alexandre Theocharides; Maurizio Ferrari; Heinz Gisslinger; Robert Kralovics; Laura Cremonesi; Radek C Skoda; Mario Cazzola
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
Blood 2008;111(3):1686-9.
2008: Giovanni Barosi; Ruben A Mesa; J Thiele; Francisco Cervantes; Peter J Campbell; Srdan Verstovsek; Brigitte Dupriez; Ross Levine; Francesco Passamonti; J Gotlib; John T Reilly; A M Vannucchi; C A Hanson; Lawrence Solberg; A Orazi; Ayalew Tefferi
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Leukemia 2008;22(2):437-8.
2008: Emanuela Boveri; Francesco Passamonti; Elisa Rumi; Daniela Pietra; Chiara Elena; Luca Arcaini; Cristiana Pascutto; Alessandro Castello; Mario Cazzola; Umberto Magrini; Mario Lazzarino
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
British journal of haematology 2008;140(2):162-8.
2007: Elisa Rumi; Francesco Passamonti; Matteo Della Porta; Chiara Elena; Luca Arcaini; Laura Vanelli; Cecilia Del Curto; Daniela Pietra; Emanuela Boveri; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5630-5.
2007: Francesco Passamonti; Maria Luigia Randi; Elisa Rumi; Ester Pungolino; Chiara Elena; Daniela Pietra; Margherita Scapin; Luca Arcaini; Fabiana Tezza; Remigio Moratti; Cristiana Pascutto; Fabrizio Fabris; Enrica Morra; Mario Cazzola; Mario Lazzarino
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation.
Blood 2007;110(2):485-9.
2007: Elisa Rumi; Francesco Passamonti; Silvia Zibellini; Miriam Martinetti; Luca Arcaini; Chiara Elena; Mario Cazzola; Mario Lazzarino
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia.
Leukemia & lymphoma 2007;48(4):805-7.
2007: Valeria Brazzelli; Francesca Prestinari; Tania Barbagallo; Claudia Rona; Ester Orlandi; Francesco Passamonti; Franco Locatelli; Marco Zecca; S Villani; Giovanni Borroni
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients.
Journal of the European Academy of Dermatology and Venereology : JEADV 2007;21(3):384-7.
2007: Francesco Passamonti; Elisa Rumi; Daniela Pietra; Mario Lazzarino; Mario Cazzola
JAK2 (V617F) mutation in healthy individuals.
British journal of haematology 2007;136(4):678-9.
2007: Luca Arcaini; Sara Burcheri; Andrea Rossi; Marco Paulli; RAFFAELE BRUNO; Francesco Passamonti; Ercole Brusamolino; Alfredo Molteni; Alessandro Pulsoni; m christina cox; Lorella Orsucci; A Fabbri; Maurizio Frezzato; Maria Teresa Voso; Francesco Zaja; Francesca Montanari; Michele Merli; Cristiana Pascutto; Enrica Morra; Sergio Cortelazzo; Mario Lazzarino
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):346-50.
2007: Luca Arcaini; Marco Paulli; Sara Burcheri; Andrea Rossi; Michele Spina; Francesco Passamonti; Marco Lucioni; Teresio Motta; Vincenzo Canzonieri; Mauro Montanari; Emanuela Bonoldi; Andrea Gallamini; Lilj Uziel; Monica Crugnola; Antonio Ramponi; Francesca Montanari; Cristiana Pascutto; Enrica Morra; Mario Lazzarino
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.
British journal of haematology 2007;136(2):301-4.
2007: Luca Arcaini; Sara Burcheri; Andrea Rossi; Cristiana Pascutto; Francesco Passamonti; Ercole Brusamolino; Marco Paulli; Ester Orlandi; Maurizio Buelli; Piera Viero; Marco Lucioni; Francesca Montanari; Michele Merli; Sergio Cortelazzo; Mario Lazzarino
Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):182-6.
2006: Ercole Brusamolino; BAIO AMBROGIA; Ester Orlandi; Luca Arcaini; Francesco Passamonti; Vassiliki Griva; William Casagrande; Cristiana Pascutto; Pietro Franchini; Mario Lazzarino
Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6487-93.
2006: Elisa Rumi; Francesco Passamonti; Daniela Pietra; Matteo Della Porta; Luca Arcaini; Sabrina Boggi; Chiara Elena; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Cancer 2006;107(9):2206-11.
2006: Luca Arcaini; Nora Colombo; Paolo Bernasconi; Silvia Calatroni; Francesco Passamonti; Ester Orlandi; Maurizio Bonfichi; Sara Burcheri; Matteo Della Porta; Elisa Rumi; Francesca Montanari; Alessandra Algarotti; Cristiana Pascutto; Mario Lazzarino
Role of the molecular staging and response in the management of follicular lymphoma patients.
Leukemia & lymphoma 2006;47(6):1018-22.
2006: Francesco Passamonti; Elisa Rumi; Daniela Pietra; Matteo Della Porta; Emanuela Boveri; Cristiana Pascutto; Laura Vanelli; Luca Arcaini; Sara Burcheri; Luca Malcovati; Mario Lazzarino; Mario Cazzola
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.
Blood 2006;107(9):3676-82.
2006: Luca Arcaini; Sara Burcheri; Andrea Rossi; Francesco Passamonti; Marco Paulli; Emanuela Boveri; Ercole Brusamolino; Ester Orlandi; Alfredo Molteni; Alessandro Pulsoni; m christina cox; Lorella Orsucci; Alberto Fabbri; Maurizio Frezzato; Maria Teresa Voso; Francesco Zaja; Francesca Montanari; Cristiana Pascutto; Enrica Morra; Sergio Cortelazzo; Mario Lazzarino
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination.
The oncologist 2006;11(3):285-91.
2006: Luca Arcaini; Nora Colombo; Francesco Passamonti; Sara Burcheri; Ester Orlandi; Ercole Brusamolino; Matteo Della Porta; Elisa Rumi; Francesca Montanari; Cristiana Pascutto; Marco Paulli; Mario Lazzarino
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.
Leukemia research 2006;30(3):277-82.
2006: Mario Cazzola; Francesco Passamonti
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders.
Haematologica 2006;91(2):159.
2006: Elisa Rumi; Francesco Passamonti; Emanuela Boveri; Mara De Amici; Cesare Astori; Marta Braschi; Carlo Castagnola; Umberto Magrini; Mario Cazzola; Mario Lazzarino
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia.
American journal of hematology 2006;81(2):124-7.
2005: Robert Kralovics; Soon-Siong Teo; Andreas S Buser; Martin H Brutsche; Ralph Tiedt; André Tichelli; Francesco Passamonti; Daniela Pietra; Mario Cazzola; Radek C Skoda
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.
Blood 2005;106(10):3374-6.
2005: Valeria Brazzelli; Francesca Prestinari; Elena Roveda; Tania Barbagallo; Eleonora Bellani; Camilla Vassallo; Ester Orlandi; Francesco Passamonti; Giovanni Borroni
Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
Journal of the American Academy of Dermatology 2005;53(5 Suppl 1):S240-3.
2005: Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7594-603.
2005: Francesco Passamonti; Elisa Rumi; Luca Arcaini; Carlo Castagnola; Monia Lunghi; Paolo Bernasconi; Matteo Giovanni Della Porta; Nora Columbo; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Leukemic transformation of polycythemia vera: a single center study of 23 patients.
Cancer 2005;104(5):1032-6.
2005: Francesco Passamonti; Daniela Pietra; Elisa Rumi; Luca Arcaini; Matteo Della Porta; Luca Malcovati; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.
Leukemia 2005;19(5):888-9.
2005: Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; André Tichelli; Mario Cazzola; Radek C Skoda
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
The New England journal of medicine 2005;352(17):1779-90.
2005: Mario Lazzarino; Luca Arcaini; Ester Orlandi; Isabella Iacona; Paolo Bernasconi; Silvia Calatroni; Marzia Varettoni; Luciano Isa; Ercole Brusamolino; Maurizio Bonfichi; Francesco Passamonti; Sara Burcheri; Cristiana Pascutto; Mario Regazzi
Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
Oncology 2005;68(2-3):146-53.
2005: Camilla Vassallo; Francesco Passamonti; Raffaello Cananzi; Valeria Brazzelli; Marco Ardigò; Mario Lazzarino; Giovanni Borroni
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases.
Acta dermato-venereologica 2005;85(1):76-7.
2004: Francesco Passamonti; Elisa Rumi; Ester Pungolino; Lucia Malabarba; Paola Bertazzoni; Marina Valentini; Ester Orlandi; Luca Arcaini; Ercole Brusamolino; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
The American journal of medicine 2004;117(10):755-61.
2004: Francesco Passamonti; Mario Cazzola
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Haematologica 2004;89(11):1284.
2004: Francesco Passamonti; Daniela Pietra; Lucia Malabarba; Elisa Rumi; Matteo Della Porta; Luca Malcovati; Maurizio Bonfichi; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders.
British journal of haematology 2004;126(5):650-6.
2004: Francesco Passamonti; Elisa Rumi; Lucia Malabarba; Luca Arcaini; Ester Orlandi; Ercole Brusamolino; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Annals of hematology 2004;83(8):495-7.
2004: Luca Arcaini; Ester Orlandi; Monica Scotti; Ercole Brusamolino; Francesco Passamonti; Sara Burcheri; Nora Colombo; Laura Vanelli; Giovanni Sbalzarini; Mario Lazzarino
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
Clinical lymphoma 2004;4(4):250-2.
2004: Luca Arcaini; Marco Paulli; Emanuela Boveri; Daniele Vallisa; Patrizia Bernuzzi; Ester Orlandi; Paolo Incardona; Ercole Brusamolino; Francesco Passamonti; Sara Burcheri; Claudio Schena; Cristiana Pascutto; Luigi Cavanna; Umberto Magrini; Mario Lazzarino
Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Cancer 2004;100(1):107-15.
2003: Francesco Passamonti; Laura Vanelli; Lucia Malabarba; Elisa Rumi; Ester Pungolino; Luca Malcovati; Cristiana Pascutto; Enrica Morra; Mario Lazzarino; Mario Cazzola
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Haematologica 2003;88(10):1123-9.
2003: Francesco Passamonti; Mario Lazzarino
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Leukemia & lymphoma 2003;44(9):1483-8.
2003: Francesco Passamonti; Lucia Malabarba; Ester Orlandi; Claudia Baratè; Angelo Canevari; Ercole Brusamolino; Maurizio Bonfichi; Luca Arcaini; Sabrina Caberlon; Cristiana Pascutto; Mario Lazzarino
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
Haematologica 2003;88(1):13-8.
2002: Paolo Bernasconi; Marina Boni; Paola Maria Cavigliano; Silvia Calatroni; Ercole Brusamolino; Francesco Passamonti; G Volpe; A Pistorio; Ilaria Giardini; Barbara Rocca; Marilena Caresana; Mario Lazzarino; Carlo Bernasconi
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Leukemia 2002;16(10):2078-83.
2002: Francesco Passamonti; Lucia Malabarba; Ester Orlandi; Cristiana Pascutto; Ercole Brusamolino; Cesare Astori; Claudia Baratè; Angelo Canevari; Alessandro Corso; Paolo Bernasconi; Mario Cazzola; Mario Lazzarino
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
British journal of haematology 2002;116(4):855-61.
2001: Alessandro Corso; Luca Arcaini; Silvia Mangiacavalli; Cesare Astori; Ester Orlandi; Angela Lorenzi; Francesco Passamonti; Catherine Klersy; Cristiana Pascutto; A Canevari-Sciorati; Mario Lazzarino
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
Haematologica 2001;86(4):394-8.
2001: Camilla Vassallo; Francesco Passamonti; Serena Merante; Marco Ardigò; G Nolli; Silvia Mangiacavalli; Giovanni Borroni
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia.
Clinical and experimental dermatology 2001;26(2):141-8.
2000: Ercole Brusamolino; F Lunghi; Ester Orlandi; Cesare Astori; Francesco Passamonti; C Baraté; Guido Pagnucco; BAIO AMBROGIA; Pietro Franchini; Mario Lazzarino; Carlo Bernasconi
Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
Haematologica 2000;85(10):1032-9.
2000: Francesco Passamonti; Ercole Brusamolino; Mario Lazzarino; C Baraté; Catherine Klersy; Ester Orlandi; Angelo Canevari; G Castelli; Serena Merante; Carlo Bernasconi
Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
Haematologica 2000;85(10):1011-8.
1999: Monica Balzarotti; S Grisanti; K Granzow; A Saladini; A Sala; Andrea Nozza; Alfredo Molteni; Francesco Passamonti; Carmelo Carlo-Stella; A Santoro; Salvatore Siena
Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Seminars in oncology 1999;26(2 Suppl 7):66-71.
1998: Ercole Brusamolino; Francesco Passamonti; Guido Pagnucco; Carlo Castagnola; Mario Lazzarino; Carlo Bernasconi
Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
Haematologica 1998;83(4):323-8.